Natural killer (NK) cell engagers binding to NKp46 and BCMA variants with Fc-engineering

US12195555B2 · kind B2 · utility

Inventors

• Nicolas Gourdin · Marseilles, FR
• Laurent Gauthier · Toulouse, FR
• Alexandre TANG · Paris, FR
• Marielle CHIRON · Paris, FR
• Angela VIRONE-ODDOS · Paris, FR
• Alessandro MASIERO · Paris, FR
• Jochen BENINGA · Frankfurt am Main, DE
• Ingo Focken · Hofheim, DE
• Sambasiva Rao · Franklin, US
• Yanfeng Zhou · Boxborough, US
• Leila Sevigny · Westborough, US

Key dates

• Filing date: Sep 19, 2023
• Grant date: Jan 14, 2025
• Expiry date: Sep 19, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor.The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).